Information  X 
Enter a valid email address

EPIC/TIDM matching '0G99'

Date
Time Source
Company
Announcement
17 Mar 2021 7:00 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business and Financial Update – FY 2020
08 Mar 2021 7:00 am GNW Factsheet Oxurion NV (0G99) OXURION to Participate in Upcoming Investor Meetings
20 Jan 2021 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
07 Jan 2021 7:00 am GNW Factsheet Oxurion NV (0G99) OXURION to Participate in Upcoming Investor Meetings
09 Nov 2020 6:30 am GNW Factsheet Oxurion NV (0G99) OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
22 Oct 2020 5:47 pm GNW Factsheet Oxurion NV (0G99) ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program
15 Oct 2020 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update – Q3 2020
13 Oct 2020 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
08 Oct 2020 7:00 am GNW Factsheet Oxurion NV (0G99) Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET
05 Oct 2020 9:00 am GNW Factsheet Oxurion NV (0G99) Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020
29 Sep 2020 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4
17 Sep 2020 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update - H1 2020
14 Sep 2020 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
11 Sep 2020 7:15 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
01 Sep 2020 6:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
03 Aug 2020 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
07 May 2020 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update - Q1 2020
12 Mar 2020 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update – FY 2019
09 Feb 2020 9:00 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference
05 Feb 2020 6:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference
19 Dec 2019 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
18 Oct 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update – Q3 2019
09 Oct 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco
09 Sep 2019 4:40 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME
05 Sep 2019 4:40 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update – H1 2019
04 Sep 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)
02 Sep 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
20 Aug 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
01 Jul 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment
11 Jun 2019 6:30 am GNW Factsheet Oxurion NV (0G99) ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies
06 Jun 2019 6:00 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
08 May 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV : Oxurion NV Business Update - Q1 2019
24 Apr 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
04 Apr 2019 6:30 am GNW Factsheet Oxurion NV (0G99) Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule
07 Mar 2019 4:45 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business Update - FY 2018
28 Feb 2019 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
04 Feb 2019 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
19 Oct 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) Oxurion NV Business Update - Q3 2018
20 Sep 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
  6:30 am GNW Factsheet ThromboGenics NV (0G99) Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
17 Sep 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
10 Sep 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit
06 Sep 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Business Update - H1 2018
03 Sep 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics becomes "Oxurion"
19 Jul 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
27 Jun 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Plans Name Change to "Oxurion"
21 Jun 2018 7:00 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
25 May 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
23 May 2018 7:00 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
09 May 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Business Update - Q1 2018
06 Apr 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema
04 Apr 2018 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
15 Mar 2018 4:40 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Business Update - FY 2017
08 Dec 2017 6:30 am GNW Factsheet ThromboGenics NV (0G99) Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate
08 Nov 2017 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer
20 Oct 2017 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics Business Update - Q3 2017
09 Oct 2017 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR
28 Sep 2017 4:35 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
27 Sep 2017 11:05 pm GNW Factsheet ThromboGenics NV (0G99) ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
18 Sep 2017 6:30 am GNW Factsheet ThromboGenics NV (0G99) ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)


Company Announcements Archive »


a d v e r t i s e m e n t